114 related articles for article (PubMed ID: 11958663)
21. Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells?
Bellan C; Lazzi S; Zazzi M; Lalinga AV; Palummo N; Galieni P; Marafioti T; Tonini T; Cinti C; Leoncini L; Pileri SA; Tosi P
Diagn Mol Pathol; 2002 Mar; 11(1):2-8. PubMed ID: 11854595
[TBL] [Abstract][Full Text] [Related]
22. Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes.
Wróel T; Mazur G; Dziegiel P; Jeleń M; Szuba A; Kuliczkowski K; Zabel M
Folia Histochem Cytobiol; 2006; 44(1):43-7. PubMed ID: 16584091
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
24. HER 2/neu expression and gene amplification in colon cancer.
Nathanson DR; Culliford AT; Shia J; Chen B; D'Alessio M; Zeng ZS; Nash GM; Gerald W; Barany F; Paty PB
Int J Cancer; 2003 Jul; 105(6):796-802. PubMed ID: 12767065
[TBL] [Abstract][Full Text] [Related]
25. Detection of immunoglobulin heavy chain gene rearrangements in classic hodgkin lymphoma using commercially available BIOMED-2 primers.
Chute DJ; Cousar JB; Mahadevan MS; Siegrist KA; Silverman LM; Stoler MH
Diagn Mol Pathol; 2008 Jun; 17(2):65-72. PubMed ID: 18382369
[TBL] [Abstract][Full Text] [Related]
26. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.
Molina R; Ciocca DR; Tandon AK; Allred DC; Clark GM; Chamness GC; Gullick WJ; McGuire WL
Anticancer Res; 1992; 12(6B):1965-71. PubMed ID: 1363511
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer.
Kohlberger P; Loesch A; Koelbl H; Breitenecker G; Kainz C; Gitsch G
Cancer Lett; 1996 Jan; 98(2):151-5. PubMed ID: 8556702
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients.
Sappino AP; Seelentag W; Pelte MF; Alberto P; Vassalli P
Blood; 1990 Feb; 75(4):958-62. PubMed ID: 2302463
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas.
Cavalot A; Martone T; Roggero N; Brondino G; Pagano M; Cortesina G
Head Neck; 2007 Jul; 29(7):655-64. PubMed ID: 17315173
[TBL] [Abstract][Full Text] [Related]
30. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
31. [DNA and RNA synthesis in benign and malignant lymphomas].
Theml H; Trepel F; Rastetter J; Begemann H
Klin Wochenschr; 1967 Jun; 45(12):609-18. PubMed ID: 4898318
[No Abstract] [Full Text] [Related]
32. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.
Villella JA; Cohen S; Smith DH; Hibshoosh H; Hershman D
Int J Gynecol Cancer; 2006; 16(5):1897-902. PubMed ID: 17009989
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
Têtu B; Brisson J
Cancer; 1994 May; 73(9):2359-65. PubMed ID: 7909490
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases.
Laurent C; Do C; Gourraud PA; de Paiva GR; Valmary S; Brousset P
Medicine (Baltimore); 2015 Jun; 94(25):e987. PubMed ID: 26107683
[TBL] [Abstract][Full Text] [Related]
35. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?
Bladergroen BA; Meijer CJ; ten Berge RL; Hack CE; Muris JJ; Dukers DF; Chott A; Kazama Y; Oudejans JJ; van Berkum O; Kummer JA
Blood; 2002 Jan; 99(1):232-7. PubMed ID: 11756176
[TBL] [Abstract][Full Text] [Related]
36. Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.
Szvalb S; Stein M; Gershuny A; Gez E; Hadary A; Zidan J
Leuk Lymphoma; 2009 May; 50(5):736-40. PubMed ID: 19452317
[TBL] [Abstract][Full Text] [Related]
37. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
38. Clusterin expression in malignant lymphomas: a survey of 266 cases.
Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ
Mod Pathol; 2002 Nov; 15(11):1221-6. PubMed ID: 12429802
[TBL] [Abstract][Full Text] [Related]
39. Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.
Fernández-Vega I; Quirós LM; Santos-Juanes J; Pane-Foix M; Marafioti T
Virchows Arch; 2015 Feb; 466(2):229-35. PubMed ID: 25433814
[TBL] [Abstract][Full Text] [Related]
40. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
